Immunocore Holdings (IMCR) EBT Margin (2021 - 2026)
Immunocore Holdings (IMCR) posted EBT Margin of 12.44% for Q1 2026, up 182.3% sequentially from 15.12% in Q4 2025, and up 596.0% YoY from 1.79% in Q1 2025.
Powered by 
Analysis
Immunocore Holdings (IMCR) EBT Margin (2021 - 2026) Analysis & Trends
Immunocore Holdings has reported EBT Margin for 6 years, with the latest figure at 12.44% in Q1 2026.
- Quarterly EBT Margin rose 596.0% year-over-year to 12.44% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2.89% (up 394.0% YoY) and the FY2025 annual result came in at 4.77%, up 1229.0% from the prior year.
- EBT Margin grew to 12.44% in Q1 2026 per IMCR's latest filing, from 15.12% in the prior quarter.
- Over five years, EBT Margin peaked at 12.44% in Q1 2026 and troughed at 55.57% in Q2 2022.
- A 5-year average of 16.62% and a median of 14.28% in 2024 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2023: EBT Margin surged 55664 bps in 2022, then sank 1097 bps in 2023.
- Over 5 years, EBT Margin stood at 48.56% in 2022, then grew by 25 bps to 36.55% in 2023, then gained by 19 bps to 29.53% in 2024, then jumped by 49 bps to 15.12% in 2025, then jumped by 182 bps to 12.44% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 12.44%, 15.12%, and 0.29% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Immunocore Holdings | 1.85 Bn | 965.54 Mn | 114.84 Mn | -0.44% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.44% |
| Mar 31, 2026 | 12.44% |
| Dec 31, 2025 | -15.12% |
| Sep 30, 2025 | 0.29% |
| Jun 30, 2025 | -9.90% |
| Mar 31, 2025 | 6.48% |
| Dec 31, 2024 | -29.53% |
| Sep 30, 2024 | 7.59% |
| Jun 30, 2024 | -13.44% |
| Mar 31, 2024 | -34.15% |
| Dec 31, 2023 | -36.55% |
| Sep 30, 2023 | 1.13% |
| Jun 30, 2023 | -28.15% |
| Mar 31, 2023 | -35.05% |
| Dec 31, 2022 | -48.01% |
| Sep 30, 2022 | 12.10% |
| Jun 30, 2022 | -55.57% |
| Dec 31, 2021 | -594.19% |
| Sep 30, 2021 | -544.55% |